Malignant hyperthermia (MH) susceptibility is a dominantly inherited disorder in which volatile anesthetics trigger aberrant Ca 2+ release in skeletal muscle and a potentially fatal rise in perioperative body temperature. Mutations causing MH susceptibility have been identified in two proteins critical for excitation-contraction (EC) coupling, the type 1 ryanodine receptor (RyR1) and Ca V 1.1, the principal subunit of the L-type Ca 2+ channel. All of the mutations that have been characterized previously augment EC coupling and/or increase the rate of L-type Ca 2+ entry. The Ca V 1.1 mutation R174W associated with MH susceptibility occurs at the innermost basic residue of the IS4 voltage-sensing helix, a residue conserved among all Ca V channels [Carpenter D, et al. (2009) BMC Med Genet 10:104-115.]. To define the functional consequences of this mutation, we expressed it in dysgenic (Ca V 1.1 null) myotubes. Unlike previously described MH-linked mutations in Ca V 1.1, R174W ablated the L-type current and had no effect on EC coupling. Nonetheless, R174W increased sensitivity of Ca 2+ release to caffeine (used for MH diagnostic in vitro testing) and to volatile anesthetics. Moreover, in Ca V 1.1 R174W-expressing myotubes, resting myoplasmic Ca 2+ levels were elevated, and sarcoplasmic reticulum (SR) stores were partially depleted, compared with myotubes expressing wild-type Ca V 1.1. Our results indicate that Ca V 1.1 functions not only to activate RyR1 during EC coupling, but also to suppress resting RyR1-mediated Ca 2+ leak from the SR, and that perturbation of Ca V 1.1 negative regulation of RyR1 leak identifies a unique mechanism that can sensitize muscle cells to MH triggers.
Malignant hyperthermia (MH) susceptibility is a dominantly inherited disorder in which volatile anesthetics trigger aberrant Ca 2+ release in skeletal muscle and a potentially fatal rise in perioperative body temperature. Mutations causing MH susceptibility have been identified in two proteins critical for excitation-contraction (EC) coupling, the type 1 ryanodine receptor (RyR1) and Ca V 1.1, the principal subunit of the L-type Ca 2+ channel. All of the mutations that have been characterized previously augment EC coupling and/or increase the rate of L-type Ca 2+ entry. The Ca V 1.1 mutation R174W associated with MH susceptibility occurs at the innermost basic residue of the IS4 voltage-sensing helix, a residue conserved among all Ca V channels [Carpenter D, et To define the functional consequences of this mutation, we expressed it in dysgenic (Ca V 1.1 null) myotubes. Unlike previously described MH-linked mutations in Ca V 1.1, R174W ablated the L-type current and had no effect on EC coupling. Nonetheless, R174W increased sensitivity of Ca 2+ release to caffeine (used for MH diagnostic in vitro testing) and to volatile anesthetics. Moreover, in Ca V 1.1 R174W-expressing myotubes, resting myoplasmic Ca 2+ levels were elevated, and sarcoplasmic reticulum (SR) stores were partially depleted, compared with myotubes expressing wild-type Ca V 1.1. Our results indicate that Ca V 1.1 functions not only to activate RyR1 during EC coupling, but also to suppress resting RyR1-mediated Ca 2+ leak from the SR, and that perturbation of Ca V 1.1 negative regulation of RyR1 leak identifies a unique mechanism that can sensitize muscle cells to MH triggers.
1,4-dihydropyridine receptor | α IS M alignant hyperthermia (MH) is a potentially fatal, pharmacogenetic disorder that can be triggered by depolarizing muscle relaxants or halogenated anesthetics (1) . Following exposure to one of these triggers, MH-susceptible individuals enter a hypermetabolic crisis characterized by tachycardia, muscle rigidity, rhabdomyolysis, increased oxidative/nitrosative stress, mitochondrial damage, acidosis, hypercapnia, and renal failure leading ultimately to death. Currently, the only means to pharmacologically terminate an MH crisis is immediate administration of the hydantoin derivative dantrolene (2) .
MH has long been linked to defective excitation-contraction (EC) coupling in skeletal muscle (3) . Ordinarily, EC coupling in skeletal muscle occurs in response to depolarization of the plasma membrane, which causes conformational changes of Ltype Ca 2+ channels containing Ca V 1.1 as the principal subunit (4-6). These voltage-dependent conformational changes result in (i) activation of the L-type Ca 2+ current and (ii) the activation of Ca 2+ release from the sarcoplasmic reticulum (SR) via type 1 ryanodine receptors (RyR1). Importantly, activation of RyR1 in skeletal muscle does not depend on the L-type Ca 2+ current but, rather, is linked directly to the conformational changes of the Ltype channels ("conformational coupling") (4, 7, 8) .
The vast majority of mutations (>180) associated with MH lie in the gene encoding RyR1 (9) , but three individual mutations have been identified in the gene encoding Ca V 1.1 (10) (11) (12) (13) . Previously characterized mutations in either channel have been found to promote activation of RyR1 during EC coupling and/or to enhance Ca 2+ entry via Ca V 1.1 (13) (14) (15) (16) (17) (18) (19) (20) (21) . Thus, it has been proposed that augmented Ca 2+ movements via the EC coupling pathway or via the L-type current underlie the fulminant response to MH triggers.
In this study, we describe the unexpected functional consequences of the recently identified R174W MH-causing mutation in Ca V 1.1 (10) . In particular, we have found that the R174W mutation ablates activation of the L-type Ca 2+ current but has surprisingly little effect on the Ca V 1.1-dependent activation of RyR1 Ca 2+ release in response to depolarization. Strikingly, however, dysgenic (Ca V 1.1 null) myotubes expressing Ca V 1.1 R174W had elevated resting myoplasmic Ca 2+ levels, depressed SR Ca 2+ store content, and a greatly increased sensitivity to volatile anesthetics. Thus, it appears that the R174W mutation perturbs resting coupling between Ca V 1.1 and RyR1, promoting RyR1 leak (22) , and that altered resting coupling represents a unique mechanism for the pathogenesis of MH.
Results
R174W Mutation in Ca V 1.1 Ablates L-Type Ca 2+ Current. Because the R174W mutation occurs at a highly conserved position in a region of Ca V 1.1 (IS4) known to be important in sensing changes in membrane potential (23, 24) , we first examined whether the R174W mutation affected the ability of Ca V 1.1 to function as an Ltype Ca 2+ channel. For this, we constructed a YFP-Ca V 1.1 R174W fusion construct and expressed the mutant channel in dysgenic Author contributions: J.M.E., R.A.B., P.M.H., I.N.P., J.R.L., K.G.B., and P.D.A. designed research; J.M.E., R.A.B., O.M., F.A., and J.R.L. performed research; T.F.M. contributed new reagents/analytic tools; J.M.E., R.A.B., I.N.P., J.R.L., K.G.B., and P.D.A. analyzed data; and J.M.E., R.A.B., I.N.P., J.R.L., K.G.B., and P.D.A. wrote the paper.
(effectively Ca V 1.1 null) myotubes. Remarkably, YFP-Ca V 1.1 R174W yielded no inward Ca 2+ current under our standard recording conditions (n = 7; Fig. 1A ) even though the fluorescence arising from the YFP tag indicated normal expression and targeting of the mutant channel (Fig. S1) . In contrast to YFP-Ca V 1.1, which predictably produced robust L-type current (−6.1 ± 0.7 pA/pF at +50 mV, n = 32; Fig. 1B ), YFP-Ca V 1.1 R174W had an I-V relationship that was nearly superimposable on that of naive dysgenic myotubes ( Fig. 1C and Table S1 ). To determine whether the absence of L-type current in YFP-Ca V 1.1 R174W-expressing myotubes was a consequence of fewer channels present in the membrane, we recorded intramembrane charge movements. Myotubes expressing YFP-Ca V 1.1 R174W produced maximal charge movement (6.5 ± 0.7 nC/μF, n = 7; Fig. 1D ) that was similar to that of YFP-Ca V 1.1-expressing myotubes (7.6 ± 0.9 nC/μF, n = 12; P > 0.05, unpaired t test; Fig. 1E and Table S1 ) and was substantially larger than that of naive dysgenic myotubes (1.6 ± 0.2 nC/ μF, n = 6; P < 0.001, ANOVA; Fig. 1F and Table S1 ). Thus, the absence of L-type current in YFP-Ca V 1.1 R174W-expressing myotubes was not a consequence of poor membrane expression of the mutant channel. We observed no clear difference in the voltage dependence of charge movement between YFP-Ca V 1.1-and YFPCa V 1.1 R174W-expressing myotubes (V Q = −7.4 ± 2.0 vs. −6.4 ± 2.4 mV, respectively; P > 0.05, unpaired t test; Fig. 1F and Table S1 ).
EC Coupling Is Little Affected by the Ca V 1.1 R174W Mutation. To determine whether the R174W mutation altered EC coupling, as has been demonstrated for other MH-causing mutations in either RyR1 (14) (15) (16) (17) (18) (19) (20) (25) (26) (27) or Ca V 1.1 (21), we measured myoplasmic Ca 2+ transients in the whole-cell configuration. As shown in Fig. 2A , dysgenic myotubes expressing YFP-Ca V 1.1 produced robust Ca 2+ transients with a mean ΔF/F max of 1.82 ± 0.63 (n = 11) and an activation midpoint (V F ) of 14.0 ± 2.5 mV. Dysgenic myotubes expressing YFP-Ca V 1.1 R174W yielded Ca 2+ transients that were similar both in magnitude (ΔF/F max = 1.85 ± 0.49, n = 6; P > 0.05, unpaired t test; Fig. 2 B and C and Table  S2 ) and in voltage dependence (V F = 10.1 ± 1.5 mV; P > 0.05, unpaired t test; Table S2 ).
As an additional means to study possible alterations in the ability of Ca V 1.1 R174W to engage EC coupling, we created cell lines stably expressing either wild-type Ca V 1.1 or Ca V 1.1 R174W from dysgenic progenitor cells ( . In the case of YFP-Ca V 1.1 R174W, I-V data were collected only from the 7 myotubes where channel expression was confirmed by charge movement; no inward current was observed in 10 additional dysgenic myotubes displaying yellow fluorescence. Currents were evoked at 0.1 Hz by test potentials ranging from −20 mV through +90 mV in 10-mV increments, following a prepulse protocol (41) . Current amplitudes were normalized by linear cell capacitance (pA/pF). The smooth curve for YFP-Ca V 1.1 is plotted according to Eq. 1, with best-fit parameters presented in Table S1 . (D and E) Representative charge movements evoked from −50 mV to −30, −10, 10, and 30 mV are shown for dysgenic myotubes expressing either YFP-Ca V 1.1 R174W (D) or YFP-Ca V 1.1 (E). Charge movements were evoked at 0.1 Hz by test potentials ranging from −40 mV through +50 mV in 10-mV increments following a prepulse protocol. (F) Q-V relationships for naïve dysgenic myotubes (n = 6) or dysgenic myotubes expressing either YFPCa V 1.1 (n = 12) or YFP-Cav1.1 R174W (n = 7). The smooth curves are plotted according to Eq. 2, with respective best-fit parameters presented in Table S1 . by elevated extracellular K + . In these experiments, myotubes expressing either Ca V 1.1 or Ca V 1.1 R174W displayed virtually identical responses to elevated K + (EC 50 = 18.9 ± 0.6 mM, n = 19, and 18.0 ± 0.9 mM, n = 31, respectively; P > 0.05, t test; Fig. 2 D-F). Thus, the R174W mutation ablates the ability of Ca V 1.1 to conduct L-type Ca 2+ current but has little, if any, effect on its function to serve as the voltage sensor for EC coupling.
Hypersensitivity to the RyR1 agonist caffeine in the in vitro contracture test (IVCT) is a benchmark diagnostic assay for MH susceptibility (3, 28) . For this reason, we assessed the caffeine sensitivities of wild-type Ca V 1.1-and Ca V 1.1 R174W-expressing myotubes. At the beginning of each experiment, myotubes were first exposed to a 60-mM K + challenge to confirm channel expression. Then, myotubes were exposed to progressively higher concentrations of caffeine to elicit Ca 2+ release from the SR ( Fig. 2 G and H) . As would be expected for MH-susceptible muscle (10, 29) , Ca V 1.1 R174W-expressing myotubes were more sensitive to caffeine (EC 50 = 2.6 ± 0.2 mM, n = 28) than myotubes expressing Ca V 1.1 (EC 50 = 4.8 ± 0.4 mM, n = 24; P < 0.001, t test; Fig. 2I ). -selective microelectrodes, Ca V 1.1 R174W-expressing myotubes had an average resting Ca 2+ concentration that was nearly twice that observed in myotubes expressing wild-type Ca V 1.1 (234 ± 4 nM, n = 33 vs. 120 ± 1 nM, n = 18, respectively; P < 0.001, unpaired t test) and similar to those previously reported for other MH susceptibility genotypes (30) . The mutation also altered the effects of known MH triggers on Ca 2+ levels. In wildtype Ca V 1.1-expressing myotubes, neither isoflurane nor the more potent halothane (both 0.1% by volume) caused a change in myoplasmic Ca 2+ (120 ± 1 nM, n = 15 and 121 ± 2 nM, n = 12, respectively; P > 0.05, ANOVA; Fig. 3 ). In stark contrast, these volatile anesthetics caused myoplasmic Ca 2+ in Ca V 1.1 R174W-expressing myotubes to increase by nearly fivefold (863 ± 21 nM, n = 8 and 1,234 ± 21 nM, n = 10, respectively; P < 0.001, ANOVA; Fig. 3 ). We next investigated whether a partially depleted SR Ca 2+ store was associated with the elevation in resting myoplasmic Ca
2+
, by exposing myotubes to ionomycin (5 μM) in a nominally Ca 2+ -free medium (22) . As shown in Fig. 4 , the content of the SR Ca 2+ store was less in Ca V 1.1 R174W-expressing myotubes than in those expressing wild-type Ca V 1.1 (integrated area under transient = 16.21 ± 3.05 arbitrary fluorescence units (afu)·s, n = 39 and 31.94 ± 3.57 afu·s, n = 33, respectively; P < 0.01, t test), consistent with the idea that resting SR Ca 2+ leak is increased by Ca V 1.1 R174W. Application of the L-type channel antagonist nifedipine had little effect on resting Ca 2+ in either wild-type Ca V 1.1-expressing or Ca V 1.1 R174W-expressing myotubes (118 ± 3 nM, n = 6 and 238 ± 3 nM, n = 6, respectively; P > 0.05, ANOVA, in both cases; Table 1 ), suggesting that the elevated resting Ca 2+ levels were not a consequence of depolarization-dependent Ca V 1.1 activity. On the other hand, exposure to dantrolene decreased resting Ca 2+ in Ca V 1.1 R174W myotubes (94 ± 2, n = 10; P < 0.05, ANOVA; Table 1 ) but produced little effect on resting Ca 2+ in wild-type Ca V 1.1-expressing myotubes (89 ± 1, n = 10; P > 0.05, ANOVA; Table 1 ). Additionally, the elevation in resting Ca 2+ was partially blocked by bastadin 5, obtained from the marine sponge Ianthella basta (Table 1 ) (31). &&& , significant difference (P < 0.001, ANOVA) in resting Ca 2+ between wild-type Ca V 1.1 and Ca V 1.1 R174W control groups. ***, significant (P < 0.001, ANOVA) difference between control and anesthetic-treated Ca V 1.1 R174W-expressing myotubes. In dysgenic myotubes expressing wild-type Ca V 1.1, no significant changes in myoplasmic Ca 2+ were observed following exposure to the volatile anesthetics relative to control. 2+ transients in dysgenic myotubes expressing Ca V 1.1 (n = 33) and Ca V 1.1 R174W (n = 39). Asterisks indicate significant differences (**P < 0.01; ***P < 0.001; unpaired t test).
Discussion
The results reported here identify a mechanism for MH susceptibility fundamentally different from those ascribed to other MH-causing mutations, which either enhance entry of Ca 2+ via the L-type channel or shift the equilibrium of RyR1 toward the activated (open) state. Importantly, we find that the R174W mutation does not alter the voltage dependence of EC coupling (Fig. 2) , which indicates that this mutation does not shift the equilibrium of RyR1 toward the activated state. Furthermore, the mutation obviously does not promote L-type Ca 2+ entry (Fig.  1) . However, our results are consistent with the idea that the R174W mutation in Ca V 1.1 derepresses Ca 2+ efflux from the SR in resting muscle cells. Thus, the Ca V 1.1-RyR1 interaction appears to have three manifestations: (i) Ca V 1.1-mediated engagement of EC coupling via RyR1, (ii) RyR1-dependent retrograde enhancement of L-type current via Ca V 1.1, and (iii) Ca V 1.1-mediated suppression of a resting SR Ca 2+ leak via RyR1. Evidence for the last of these is provided by our previous work, which showed that resting SR Ca 2+ stores are reduced, and myoplasmic Ca 2+ levels are higher, in naive dysgenic (i.e., Ca V 1.1-lacking) myotubes compared with wild-type myotubes (22) , suggesting that Ca V 1.1 represses a resting Ca 2+ leak from the SR via RyR1 (Fig. 5A ). The increase in resting myoplasmic Ca 2+ in Ca V 1.1 R174W-expressing myotubes is also accompanied by a reduction in the resting SR Ca 2+ store (Fig. 4) . This leak pathway in dysgenic myotubes appears to be distinct from the conventional activated state of RyR1 because it is blocked by bastadin 5 (or bastadin 5 in the presence of ryanodine) but not by ryanodine alone (32, 33) ; bastadin 5 (B5) application also causes a partial reduction in resting myoplasmic Ca 2+ in dysgenic myotubes expressing Ca V 1.1 R174W ( Table 1) . As shown in Fig. 5B , expression of wild-type Ca V 1.1 in dysgenic myotubes represses the resting Ca 2+ leak (22) and restores both EC coupling and L-type current (6) . The R174W mutation alters the resting conformation of Ca V 1.1 such that it no longer suppresses resting Ca 2+ leak via RyR1 but does not noticeably alter its function as the voltage sensor for EC coupling (Fig. 5C ). It should be pointed out that the level of resting Ca 2+ in Ca V 1.1 R174W-expressing dysgenic myotubes (234 ± 4 nM; Table 1 ) is higher than that in naive dysgenic myotubes (163 ± 2.5 nM) (22) , which suggests that in addition to removing block of the resting RyR1 leak, the R174W mutation also serves to amplify this resting leak.
Additional evidence supporting a causative role of resting leak in MH pathogenesis is that dantrolene, the clinical "antidote" for MH crises, restores resting Ca 2+ to normal levels in dysgenic myotubes expressing Ca V 1.1 R174W (Table 1) . Thus, our findings identify a unique mechanism underlying a potentially fatal human disorder. In particular, the R174W mutation disrupts the ability of Ca V 1.1 to repress resting Ca 2+ leak from the SR via RyR1, leading to elevated resting myoplasmic Ca 2+ and increased sensitivity to MH triggers. Significantly, elevations in resting myoplasmic Ca 2+ that are not blocked by ryanodine have also been observed in dyspedic myotubes expressing eight distinct RyR1 MH-linked mutations (30) . Thus, other mutations in either Ca V 1.1 or RyR1 may potentially lead to increased resting Ca 2+ leak. Although increased SR Ca 2+ leak may represent a sensitizing mechanism, it is almost certain that multiple mechanisms are at work in MH susceptibility. In this regard, any mechanism that causes sustained, partial SR Ca 2+ store depletion would presumably result in a sustained increase in storeoperated Ca 2+ entry (34, 35) and thus increased resting myoplasmic Ca 2+ . Simply raising myoplasmic Ca 2+ would be expected to increase the efficacy of other activators (e.g., caffeine and volatile anesthetics). Moreover, chronically elevated myoplasmic Ca 2+ levels could have downstream sequelae as a result of altered mitochondrial metabolism (17, 36) .
In conclusion, we have described a unique mechanism whereby a mutation of Ca V 1.1 promotes MH susceptibility by causing an increase in resting SR Ca 2+ leak. It will be important to determine the extent to which an enhanced resting leak contributes to MH susceptibility for other Ca V 1.1 and RyR1 mutations.
Materials and Methods
Molecular Biology. YFP-Ca V 1.1 R174W was derived from the plasmid YFPCa V 1.1 (37), using the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies).
Primary Culture and cDNA Expression. All procedures involving mice were approved by the Institutional Animal Care and Use Committees of University of Colorado Denver and Harvard Medical School. Primary cultures of dysgenic myotubes were prepared as described previously (38) . Single nuclei of Data are given as mean ± SEM, with the numbers in parentheses indicating the number of myotubes tested. Control cells were exposed only to Imaging Solution (IS). Statistical differences: ***P < 0.001 vs. Ca V 1.1 (oneway ANOVA); &&& P < 0.001 vs. Ca V 1.1 R174W control. NS, no significant difference vs. Ca V 1.1 (P > 0.05, one-way ANOVA). (6) . (C) The R174W mutation alters the conformation of Ca V 1.1 such that it does not suppress resting SR Ca 2+ leak, leading to an increase in resting Ca 2+ and enhanced sensitivity to MH triggers (Left ; Fig. 3) ; the R174W mutation also ablates the ability of Ca V 1.1 to produce L-type current but has little, if any, effect on the ability of Ca V 1.1 to engage EC coupling (Right). differentiated myotubes were microinjected with 200 ng/μL plasmid cDNA encoding either YFP-Ca V 1.1 or YFP-Ca V 1.1 R174W.
Generation of Myoblasts Stably Expressing
Wild-Type Ca V 1.1 or Ca V 1.1-R174W. cDNAs encoding either wild-type Ca V 1.1 (22) or Ca V 1.1 R174W were subcloned between the LTRs of a lentiviral vector driven by an EF1α human promoter (22, 39) . The lentiviral particles were packaged by transfection of HEK 293T cells as described previously (40) . Dysgenic myoblasts were transduced with lentiviral particles and were replated with one cell per well in 96-well culture plates 24 h later. After 2-3 wk, myoblasts from 20-30 clones were plated in 96-well plates and differentiated into myotubes. To screen for expression of either Ca V 1.1 or Ca V 1.1 R174W, myotubes were loaded with Fluo-4 AM and challenged by K + depolarization (see below); positive myotubes were identified by the ability to support Ca 2+ transients in response to depolarization.
Electrophysiology. Electrophysiological experiments were performed with dysgenic myotubes expressing either YFP-Ca V 1.1 or YFP-Ca V 1.1 R174W 2 d postmicroinjection. Pipettes were fabricated from borosilicate glass and had resistances of ∼2.0 MΩ when filled with internal solution, which consisted of 140 mM Cs-aspartate, 10 mM Cs 2 -EGTA, 5 mM MgCl 2 , and 10 mM Hepes, pH 7.4, with CsOH. The external solution contained 145 mM tetraethylammonium (TEA)-Cl, 10 mM CaCl 2 , 0.002 mM tetrodotoxin, and 10 mM Hepes, pH 7.4, with TEA-OH. For measurement of charge movements, 0.5 mM CdCl 2 and 0.1 mM LaCl 3 were added to the external solution. Filtering was at 2 kHz (eight-pole Bessel filter; Frequency Devices) and digitization was either at 10 kHz (L currents) or 20 kHz (charge movements). Current-voltage (I-V) curves were fitted according to
where I is the current for the test potential V, V rev is the reversal potential, G max is the maximum Ca 2+ channel conductance, V 1/2 is the half-maximal activation potential, and k G is the slope factor. Plots of the integral of Q on as a function of test potential (V) were fitted according to
where Q max is the maximal Q on , V Q is the potential causing movement of half the maximal charge, and k Q is a slope parameter.
Whole-Cell Measurement of Ca 2+ Transients. Changes in intracellular Ca 2+ were recorded with Fluo-3 (F-3715; Invitrogen). The dye was added to the internal solution for a final concentration of 200 μM. After entry into the whole-cell configuration, a period of >5 min was used to allow the dye to diffuse into the cell interior. The peak fluorescence change (ΔF/F) for each test potential (V) was fitted according to
where (ΔF/F) max is the maximal fluorescence change, V F is the potential causing half the maximal change in fluorescence, and k F is a slope parameter. . Briefly, the point mutation was introduced using the QuikChange II XL sitedirected mutagenesis kit (200523-5; Agilent Technologies) with the forward primer 5′-GTGCTCAGACCCCTCTGGCTGGTGTCG-GGGGTG-3′ and the reverse primer 5′-CACCCCCGACACCA-GCCAGAGGGGTCTGAGCAC-3′. Sequencing of the final construct verified the presence of the point mutation.
Primary Dysgenic Myotube Culture and cDNA Expression. All procedures involving mice were approved by the Institutional Animal Care and Use Committees of the University of Colorado Denver-Anschutz Medical Campus and Harvard Medical School. Primary cultures of dysgenic (mdg/mdg) myotubes were prepared as described previously (2) . Cultures were grown for 6-7 d in a humidified 37°C incubator with 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM) (15-017-CM; Mediatech), supplemented with 10% (vol/vol) FBS/10% (vol/vol) horse serum (HyClone Laboratories). This medium was then replaced with differentiation medium (DMEM supplemented with 2% horse serum). Two to four d following the shift to differentiation medium, single nuclei were microinjected with 200 ng/μL plasmid cDNA encoding either YFP-Ca V 1.1 or YFPCa V 1.1 R174W.
Generation of Myoblasts Stably Expressing Wild-Type Ca V 1.1 or Ca V 1.1-R174W. cDNAs encoding either wild-type Ca V 1.1or Ca V 1.1 R174W were subcloned between the LTRs of a lentiviral vector driven by an EF1α human promoter (3, 4) . The lentiviral particles were subsequently packaged into HEK 293T cells by a standard method of infection (5) . dysgenic (mdg/mdg) myoblasts were transduced with lentiviral particles and were replated with one cell per well in 96-well culture plates 24 h later. After 2-3 wk, myoblasts from 20-30 clones were plated in 96-well plates and differentiated into myotubes. To screen for expression of either Ca V 1.1 or Ca V 1.1 R174W, myotubes were loaded with Fluo-4 AM and challenged by K + depolarization (see below). Positive myotubes were identified by the ability to support Ca 2+ transients in response to K + depolarization; negative and uninfected dysgenic cells showed no signal. Myoblasts expanded from positive clones were then plated in 96-well imaging plates in Ham's F-10 Media (11550-043; Invitrogen) supplemented with 20% bovine growth serum (HyClone) and 5 ng/mL FGFbasic (Thermo-Fisher Scientific). Differentiation was induced the following day by changing the external medium to DMEM (11885-084; Invitrogen) supplemented with 2% heat-inactivated horse serum (Sigma-Aldrich).
Measurement of Ionic Currents and Charge Movements. Electrophysiological experiments were performed with dysgenic myotubes expressing either YFP-Ca V 1.1 or YFP-Ca V 1.1 R174W 2 d following microinjection; expressing myotubes were identified by YFP fluorescence. Pipettes were fabricated from borosilicate glass and had resistances of ∼2.0 MΩ when filled with internal solution, which consisted of 140 mM Cs-aspartate, 10 mM Cs 2 -EGTA, 5 mM MgCl 2 , and 10 mM Hepes, pH 7.4, with CsOH. The external solution contained 145 mM tetraethylammoniumCl, 10 mM CaCl 2 , 0.002 mM tetrodotoxin, and 10 mM Hepes, pH 7.4, with tetraethylammonium-OH. For measurement of intramembrane charge movements, ionic currents were blocked by the addition of 0.5 mM CdCl 2 and 0.1 mM LaCl 3 to the external solution. Electronic compensation was used to reduce the effective series resistance (usually to <1 MΩ) and the time constant for charging the linear cell capacitance (usually to <0.5 ms). Ltype currents were corrected for linear components of leak and capacitive current by digital scaling and subtraction of the average of 11, 30-mV hyperpolarizing pulses from a holding potential of −80 mV. Charge movements were corrected for linear cell capacitance and leakage currents using a −P/8 subtraction protocol. Filtering was at 2 kHz (eight-pole Bessel filter; Frequency Devices) and digitization was either at 10 kHz (L-type currents) or at 20 kHz (charge movements). Voltage-clamp command pulses were exponentially rounded with a time constant of 50-500 μs and a 1-s prepulse to −20 mV followed by a 25-ms repolarization to −50 mV was administered before the test pulse (prepulse protocol) (6) , to inactivate endogenous Ca V 3 and Na V channels. Cell capacitance was determined by integration of a transient from −80 mV to −70 mV, using Clampex 8.0 (Molecular Devices), and was used to normalize charge movements (nC/μF) and current amplitudes (pA/pF). Current-voltage (I-V) curves were fitted according to
where I is the current for the test potential V, V rev is the reversal potential, G max is the maximum Ca 2+ channel conductance, V 1/2 is the half-maximal activation potential, and k G is the slope factor. Plots of the integral of the ON charge movement (Q on ) as a function of test potential (V) were fitted according to
where Q max is the maximal Q on , V Q is the potential causing movement of half the maximal charge, and k Q is a slope parameter. All electrophysiological experiments were performed at room temperature (∼25°C).
Measurement of Intracellular Ca
2+ Transients. Changes in intracellular Ca 2+ were recorded with Fluo-3 (F-3715; Molecular Probes). The salt form of the dye was added to the standard internal solution for a final concentration of 200 μM. After entry into the whole-cell configuration, a waiting period of >5 min was used to allow the dye to diffuse into the cell interior. A 100-W mercury illuminator and a set of fluorescein filters were used to excite the dye present in a small rectangular region of the voltage-clamped myotube. A computer-controlled shutter was used to block illumination in the intervals between test pulses. Fluorescence emission was measured by means of a fluorometer apparatus (Biomedical Instrumentation Group). The average background fluorescence was quantified before bath immersion of the patch pipette. Fluorescence data are expressed as the total change in fluorescence (ΔF/F), where ΔF represents the change in peak fluorescence from baseline during the test pulse and F is the fluorescence immediately before the test pulse minus the average background (non-Fluo-3) fluorescence. The peak value of the fluorescence change (ΔF/F) for each test potential (V) was fitted according to
where (ΔF/F) max is the maximal fluorescence change, V F is the potential causing half the maximal change in fluorescence, and k F is a slope parameter.
Ca 2+ Imaging. Differentiated dysgenic myotubes stably expressing wild-type Ca V 1.1 or Ca V 1.1 R174W were loaded with 5 μM Fluo-4 AM (Invitrogen) for 15 min at 37°C, washed three times with Imaging Solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5.5 mM glucose, 10 mM Hepes, pH 7.4, with NaOH), and placed in the stage of a Nikon TE2000 microscope coupled with a digital acquisition system (Stanford Photonics). The Ca 2+ signal was monitored using 480/30-nm excitation and 535/40-nm emission wavelengths. Elevated K + -induced depolarization was assessed by exposing myotubes to 10-s pulses of 10, 20, 30, and 60 mM K + solutions (Na + was decreased appropriately to maintain constant osmolarity). Caffeine sensitivity was evaluated by exposing myotubes to 30-s pulses of isoflurane (IS) supplemented with 0.5, 1, 3, 5, 10, and 40 mM caffeine. In both cases, a >2-min interval in IS between pulses was used to ensure recovery of the basal Ca 2+ level after each pulse. Peak responses to either elevated K + or caffeine were quantified as the integrated area under the curve for each induced Ca 2+ release event. The peak response of a given K + or caffeine concentration was then normalized by the maximal response to either agent (60 or 40 mM, respectively) and dose-response relationships were fitted by the modified Hill equation
where (ΔF/F) norm is the (ΔF/F) normalized by the maximal response, EC 50 is the concentration that produces 50% of the maximal response, X is the concentration of K + or caffeine applied, and k is a slope parameter. Resting Myoplasmic Ca 2+ Measurements. Double-barreled Ca 2+ -selective microelectrodes were prepared and calibrated as previously described (3) . Only those electrodes with a linear relationship between pCa 3 and pCa 8 (Nernstian response, 28.5 mV per pCa unit at 24°C) were used experimentally. To mimic the intracellular ionic conditions more effectively, all calibration solutions were supplemented with 1 mM Mg 2+ . All electrodes were then recalibrated after making measurements of myoplasmic Ca 2+ and the data from a microelectrode were discarded if the two calibration curves diverged >3 mV from pCa 7 to pCa 8. Myotubes were impaled with the double-barreled microelectrode and potentials were recorded via a high-impedance amplifier (WPI FD-223). The potential from the 3-M KCl barrel (V m ) was subtracted electronically from V CAE , to produce a differential Ca 2+ -specific potential (V Ca ) that represents the myoplasmic Ca 2+ concentration. V m and V Ca were filtered (30-50 KHz) to improve the signal-to-noise ratio and stored in a computer for further analysis.
Pharmacology. Caffeine (Sigma) was diluted directly into IS, and dantrolene (Sigma) was dissolved in dry DMSO to make a 25-mM stock. Nifedipine (Sigma) was dissolved in DMSO to make a 25-mM stock. Both dantrolene and nifedipine were diluted to their respective working concentrations immediately before use in the dark. Volatile anesthetics (i.e., halothane and isoflurane) were obtained from Halocarbon and Baxter, respectively. To make 0.1% vol/vol working solutions, 100% volatile anesthetic was drawn with a Hamilton syringe using a large bore flat needle, transferred to an amber bottle containing Imaging Solution, and placed in 50°C water bath for 10 min. The working solution was then sonicated at ∼45-50°C for another 10 min with periodic agitation. Bastadin 5 (B5) was extracted from lyophilized Ianthella basta sponge and was solubilized in water (7) . B5 was added to the Ringer's solution for a final concentration of 20 μM 10 min before making measurements of resting myoplasmic Ca 2+ .
Statistical Analysis. Figures were made using the software program SigmaPlot (version 11.0; SSPS). All data are presented as mean ± SEM. Statistical comparisons were made by unpaired, two-tailed t test or one-way ANOVA coupled with Tukey's t test (as appropriate), with P < 0.05 considered significant. Table S1 . L-type conductance and intramembrane charge movement No inward current (7) 6.5 ± 0.7 (7) −6.4 ± 2.4 10.0 ± 0.7 Uninjected dysgenic myotubes No inward current (17) 1.6 ± 0.2*** (6) −19.5 ± 2.1** 5.8 ± 1.9** Data are given as mean ± SEM, with the numbers in parentheses indicating the number of myotubes tested. L-type current conductance was fitted by Eq. 1 and charge movements were fitted by Eq. 2. For all of the data given, the calculated average voltage error was <5 mV. Asterisks indicate significant differences relative to YFP-Ca V 1.1 (**P < 0.005; ***P < 0.001; one-way ANOVA). Data are given as mean ± SEM, with the numbers in parentheses indicating the number of myotubes tested. All ΔF/F-V data given were fitted with Eq. 2.
